UK markets open in 2 hours 53 minutes

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.87+0.28 (+1.59%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5837.98M
Enterprise value 3846.7M
Trailing P/E N/A
Forward P/E 1-12.67
PEG ratio (5-yr expected) 10.11
Price/sales (ttm)9.77
Price/book (mrq)N/A
Enterprise value/revenue 39.87
Enterprise value/EBITDA 7-7.62

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 318.49%
S&P500 52-week change 341.88%
52-week high 321.30
52-week low 39.01
50-day moving average 317.69
200-day moving average 315.70

Share statistics

Avg vol (3-month) 3569.72k
Avg vol (10-day) 3675.11k
Shares outstanding 546.89M
Implied shares outstanding 6N/A
Float 45.81M
% held by insiders 12.38%
% held by institutions 1103.87%
Shares short (29 Apr 2021) 46.7M
Short ratio (29 Apr 2021) 414.81
Short % of float (29 Apr 2021) 414.62%
Short % of shares outstanding (29 Apr 2021) 414.28%
Shares short (prior month 30 Mar 2021) 46.99M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Mar 2021


Profit margin -205.13%
Operating margin (ttm)-170.19%

Management effectiveness

Return on assets (ttm)-23.54%
Return on equity (ttm)-301.15%

Income statement

Revenue (ttm)85.77M
Revenue per share (ttm)1.87
Quarterly revenue growth (yoy)12.90%
Gross profit (ttm)55.5M
EBITDA -111.08M
Net income avi to common (ttm)-175.94M
Diluted EPS (ttm)-3.83
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)208.2M
Total cash per share (mrq)4.44
Total debt (mrq)230.05M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.14
Book value per share (mrq)-0.22

Cash flow statement

Operating cash flow (ttm)-52.92M
Levered free cash flow (ttm)-33.42M